SG11202005781WA - Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof - Google Patents

Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Info

Publication number
SG11202005781WA
SG11202005781WA SG11202005781WA SG11202005781WA SG11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA
Authority
SG
Singapore
Prior art keywords
cerdulatinib
pharmaceutical compositions
topical skin
containing topical
skin pharmaceutical
Prior art date
Application number
SG11202005781WA
Inventor
Charles Evans
Cameron Stevenson
Marc Brown
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of SG11202005781WA publication Critical patent/SG11202005781WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
SG11202005781WA 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof SG11202005781WA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862615261P 2018-01-09 2018-01-09
US201862686509P 2018-06-18 2018-06-18
US201862765133P 2018-08-16 2018-08-16
US201862772415P 2018-11-28 2018-11-28
PCT/IB2019/000017 WO2019138291A2 (en) 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11202005781WA true SG11202005781WA (en) 2020-07-29

Family

ID=65685834

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005781WA SG11202005781WA (en) 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Country Status (17)

Country Link
US (1) US20200390689A1 (en)
EP (1) EP3737354A2 (en)
JP (1) JP2021510159A (en)
KR (1) KR20200108297A (en)
CN (1) CN111818910A (en)
AU (1) AU2019208049A1 (en)
BR (1) BR112020013976A2 (en)
CA (1) CA3087124A1 (en)
CL (1) CL2020001791A1 (en)
CO (1) CO2020008244A2 (en)
IL (1) IL275899A (en)
MX (1) MX2020007062A (en)
RU (1) RU2020124293A (en)
SG (1) SG11202005781WA (en)
TW (1) TW201938167A (en)
WO (1) WO2019138291A2 (en)
ZA (1) ZA202004104B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102395A1 (en) * 2018-06-04 2019-12-12 Chemistryrx. Topical compositions for stimulating hair growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SG10201910912TA (en) * 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
CA2830463A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2788028B1 (en) * 2011-12-08 2019-03-27 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
CN107847428A (en) * 2015-05-07 2018-03-27 纽约市哥伦比亚大学理事会 For trichogenous method and composition
JP6833816B2 (en) * 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ, インコーポレイテッド CERDULATINIB for the treatment of myeloma
CN108367006B (en) * 2015-12-04 2021-12-31 博尔托拉制药公司 Cerdulatinib for treating hematologic cancers
CA3026763A1 (en) * 2016-06-07 2017-12-14 Dermavant Sciences GmbH Topical formulations of pde-4 inhibitors and their methods of use
WO2018200786A1 (en) * 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo

Also Published As

Publication number Publication date
CO2020008244A2 (en) 2020-10-30
CL2020001791A1 (en) 2020-12-04
EP3737354A2 (en) 2020-11-18
US20200390689A1 (en) 2020-12-17
BR112020013976A2 (en) 2020-12-08
MX2020007062A (en) 2021-03-09
TW201938167A (en) 2019-10-01
IL275899A (en) 2020-08-31
KR20200108297A (en) 2020-09-17
CN111818910A (en) 2020-10-23
ZA202004104B (en) 2022-01-26
JP2021510159A (en) 2021-04-15
RU2020124293A (en) 2022-02-10
AU2019208049A1 (en) 2020-07-23
CA3087124A1 (en) 2019-07-18
WO2019138291A2 (en) 2019-07-18
WO2019138291A3 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
HK1248526A1 (en) Cosmetic and topical compositions comprising cannabigerol
EP3706741A4 (en) Pharmaceutical composition and use thereof
EP3434285A4 (en) Pharmaceutical composition and use thereof
EP3607957A4 (en) Pharmaceutical composition and cosmetic composition
ZA201904704B (en) Topical cyclosporine-containing formulations and uses thereof
EP3735258A4 (en) Topical skin care compositions
HK1259228A1 (en) Two-phase cosmetic composition and use thereof for topical application
HK1245631A1 (en) Hydroalcoholic extract of schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
GB2586731B (en) Topical skin care compositions
EP3572088A4 (en) Panax plant extract and pharmaceutical composition and use thereof
EP3697411A4 (en) Novel pharmaceutical composition and use thereof
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
EP3595693A4 (en) Cannabinoid formulations and dosage
EP3056206A4 (en) Icotinib-containing topical skin pharmaceutical composition and use thereof
EP3497080A4 (en) Pharmaceutical formulations and their use
EP3302483A4 (en) Pharmaceutical compositions and use thereof
IL275899A (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
IL261929B (en) Stable pharmaceutical compositions for topical administration and uses thereof
EP3615064A4 (en) Enriched cellular compositions and therapeutic use
ZA202100166B (en) Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof
EP3269709A4 (en) N-phenyl-n'-phenoxycarbonyl-phenylsulfonhydrazide derivative and pharmaceutical composition comprising same
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
GB201905509D0 (en) Pharmaceutical compositions and associated lits and uses
EP3718543A4 (en) Pharmaceutical composition and use thereof
EP3664800A4 (en) Therapeutic formulations and uses thereof